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T cells are an essential component of the immune response against herpes simplex virus (HSV) infection. We previously reported that
incubation of T cells with HSV-infected fibroblasts inhibits subsequent T cell antigen receptor signal transduction. In the current study, we found
that incubation of T cells with HSV-infected fibroblasts also leads to apoptosis in exposed T cells. Apoptosis was observed in Jurkat cells, a T cell
leukemia line, and also in CD4+ cells isolated from human peripheral blood mononuclear cells. Direct infection of these cells with HSV also
resulted in apoptosis. Clinical isolates of both HSV type 1 and 2 induced apoptosis in infected T cells at comparable levels to cells infected with
laboratory strains of HSV, suggesting an immune evasion mechanism that may be clinically relevant. Further understanding of these viral immune
evasion mechanisms could be exploited for better management of HSV infection.
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Effective cell-mediated immunity is critical in control of
herpes simplex virus (HSV) infection (Rinaldo and Torpey,
1993; Schmid and Rouse, 1992), and severe HSV disease can
occur in immunocompromised patients (Herget et al., 2005;
Kusne et al., 1991). HSV is characterized by a life-long
infection with intermittent reactivations in immunocompetent
people, and reactivation can occur on more than 75% of days in
some individuals (Wald et al., 1997). The pathology and
epidemiology of HSV reflect the ability of the virus to
circumvent the host's immune system. Although the immune⁎ Corresponding author. Program in Infectious Diseases, Fred Hutchinson
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doi:10.1016/j.virol.2006.09.038system in immunocompetent individuals will ultimately control
the infection, the ability of HSV to evade the local immune
responses for a limited time allows the virus to establish latent
infection and reactivate for the life of the human host.
HSV uses multiple strategies to protect infected epithelial
cells from the host's immune defenses. For example, HSV
inhibits the major histocompatibility complex class I and II
antigen presentation pathways (Favoreel et al., 2000; Koelle and
Corey, 2003). Inhibition of these pathways protects infected
cells from recognition by CD8+ and CD4+ T cells respectively.
Other examples of immune evasion mechanisms include several
HSV factors that have been reported to inhibit apoptosis and
maintain the viability of infected cells (Aubert and Blaho, 2001;
Aubert and Jerome, 2003; Goodkin et al., 2004). Identified
factors include US3 protein kinase (Jerome et al., 1999; Leopardi
and Roizman, 1996; Leopardi et al., 1997; Munger et al., 2001;
Murata et al., 2002; Purves et al., 1987), glycoprotein J (Jerome
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et al., 2003, 2000; Zhou and Roizman, 2001; Zhou and
Roizman, 2002a, 2002b), ICP10 protein kinase (Perkins et al.,
2003, 2002a, 2002b), and latency-associated transcripts (Ahmed
et al., 2002; Gupta et al., 2006; Inman et al., 2001; Perng et al.,
2000). Efficiency of inhibition depends on the specific viral
factor and the apoptotic stimulus. Our laboratory previously
reported that deletion of the US3 gene markedly reduced
inhibition of ultraviolet light induced apoptosis in HSV-infected
cells (Jerome et al., 1999), while expression of the US5 gene
(glycoprotein J) protected cells from granzyme B and Fas-
mediated cell death (Jerome et al., 2001a). Such findings
probably reflect the apoptotic pathway targeted by each anti-
apoptotic viral factor.
Despite numerous studies characterizing the anti-apoptotic
mechanisms of HSV (Aubert and Blaho, 2001; Aubert and
Jerome, 2003; Goodkin et al., 2004), immune cells infected with
HSV undergo apoptosis. HSV infection of T cells can directly
lead to apoptosis (Ito et al., 1997a, 1997b; Pongpanich et al.,
2004). Infection of HSV-specific cytotoxic T lymphocytes
(CTL) has also been reported to result in more rapid apoptosis
via “fratricide” (killing of each other) because major histocom-
patibility complex I antigen presentation is not blocked in CTL
following HSV infection (Raftery et al., 1999). In addition,
monocytoid cells (Mastino et al., 1997), dendritic cells (Bosnjak
et al., 2005; Jones et al., 2003), and macrophages (Fleck et al.,
1999) have been reported to show signs of apoptosis following
HSV infection. These findings indicate that induction of
apoptosis in key immune effector cells may be an important
mechanism of viral immune modulation.
In vivo, T cells are mostly likely to encounter HSV via
infected keratinocytes during trafficking of HSV-specific T cells
to sites of virus reactivation (Posavad et al., 1998). This
laboratory and others have previously demonstrated modulation
of T cell function when T cells are exposed to HSV-infected
fibroblasts in vitro (Posavad et al., 1993; Posavad and
Rosenthal, 1992; Sloan et al., 2003, 2006). Specifically,
cytolytic activity (Posavad et al., 1993; Posavad and Rosenthal,
1992; Sloan et al., 2003) and T cell antigen receptor (TCR)
signal transduction (Sloan et al., 2003, 2006) are impaired in T
cells following incubation with HSV-infected fibroblasts. Our
study suggested that increased apoptosis was not present in CTL
within the first 5 h following an exposure to HSV-infected
fibroblasts (Sloan et al., 2003). In addition, while we previously
reported that clinical HSV strains did not lead to caspase-3 or -8
activation in infected Jurkat cells (Jerome et al., 2001b), a recent
report demonstrated apoptosis induction in Jurkat cells at later
time points after infection with laboratory strains of HSV
(Pongpanich et al., 2004).
To determine if induction of apoptosis is a potential
mechanism by which HSV modulates T cell function, we
have carried out more detailed studies to detect apoptosis in
Jurkat cells and CD4+ T cells isolated from human peripheral
blood mononuclear cells (PBMC) that are either exposed to
HSV-infected fibroblasts or directly infected with laboratory
strains of HSV. We investigated whether induction of apoptosis
is an attribute of laboratory HSV strains by comparing inductionof apoptosis in Jurkat cells infected with laboratory strains
against cells infected with clinical isolates of HSV. We also
investigated whether apoptosis could be seen in B cells by
studying Ramos cells, a B cell lymphoma line. Finally, two
potential HSV immune modulation mechanisms, induction of
apoptosis and inhibition of TCR signaling, were studied
simultaneously to discern the relationship between the two
processes.
Results
Jurkat cells directly infected with HSV undergo apoptosis
To investigate whether HSV induces apoptosis in T cells, we
first evaluated apoptotic markers in Jurkat cells directly infected
with HSV-2. Jurkat cells were infected with HSV-2 strain HG52
at a multiplicity of infection (MOI) of 5 and analyzed for
apoptosis and necrosis at 6 h and 24 h post infection (p.i). For
this purpose, we used annexin V, a protein that binds with high
affinity to phosphatidylserine residues that become exposed on
the surface of apoptotic cells. Cells show reactivity with
annexin V before the plasma membrane loses its ability to
exclude a dye such as propidium iodide (PI). Thus, by staining
cells with a combination of fluorescently labeled annexin Vand
PI, it is possible to distinguish viable cells (annexin V−PI−),
early apoptotic cells (annexin V+PI−), and late apoptotic or
necrotic cells (annexin V+PI+). Our results indicated that HSV-2
infection induced apoptosis in Jurkat cells that could be
observed at 6 h p.i. (Fig. 1A). The percentage of early apoptotic
cells was increased at 24 h p.i., with the average of 41% of HSV-
infected cells that were annexin V+PI− compared with 8% of
mock-infected cells. There was also a corresponding increase in
annexin V+PI+ cells in HSV-infected cells at 24 h, most likely
representing an increase in late apoptotic cells.
We sought further evidence of apoptosis in HSV-2-infected
Jurkat cells by determining the percentage of cells with activated
caspase-3. Cells were labeled with antibody against activated
caspase-3 and analyzed by flow cytometry. Compared to a
baseline of 9% in mock-infected cells, 19% of HSV-infected cells
demonstrated activated caspase-3 at 6 h p.i., and the percentage
was increased to 41% at 24 h p.i. (Fig. 1B). Thus, HSV-2
infection of Jurkat cells also induced caspase-3 activation.
To determine dose and time dependence of apoptosis
induction, Jurkat cells were infected with HSV-2 strain HG52
at different MOI and analyzed for annexin V binding at 6, 12,
18, and 24 h p.i. A step-wise increase in apoptotic cells was
noted over time in infected cells (Fig. 1C). A minimal increase
in the percentage of annexin V+ cells was observed above MOI
of 5, suggesting that the viral infection of Jurkat cells leads to
apoptosis rather than non-viral stimulation from the inoculum.
CD4+ cells isolated from human PBMC undergo apoptosis
with HSV infection
To assess if our findings with Jurkat cells are applicable to
primary T cells, CD4+ cells were isolated from human PBMC
following stimulation with phytohemagglutinin and IL-2.
Fig. 2. CD4+ cells infected with HSV-2 undergo apoptosis. CD4+ cells isolated
from human PBMC were mock infected or infected with HSV-2 HG52 at an
MOI of 5 and analyzed for apoptosis at 24 h, 48 h, and 72 h p.i. (A) Percentages
of annexin V+ cells by flow cytometry with standard error bars of 3–4
independent experiments. (B) Percentages of annexin V+/PI− cells by flow
cytometry analysis with standard error bars of 3–4 independent experiments. (C)
Percentages of cells staining with anti-activated caspase-3 antibody at 24 h, 48 h,
and 72 h p.i. with standard error bars of 3 independent experiments.
Fig. 1. Induction of apoptosis by HSV-2 infection in Jurkat cells. (A) Jurkat cells
were mock infected or infected with HSV-2 HG52 at an MOI of 5 and analyzed
for apoptosis with annexin V and PI binding at 6 h and 24 h p.i. One
representative flow cytometry experiment out of 4 independent experiments is
shown. Mean percentages of annexin V+PI− (early apoptotic) and annexin V+PI+
(late apoptotic or necrotic) cells of the 4 independent experiments are noted. (B)
Flow cytometry analysis of mock-infected (dashed line) and HSV-2-infected
(solid line) cells stained with anti-activated caspase-3 antibody at 6 h and 24 h p.i.
(C) Percentages of annexin V+ Jurkat cells over time after infection with varying
MOI of HSV-2. Jurkat cells were mock infected or infected with HSV-2 at MOI
of 1, 5, 10, and 25. Percentages of annexin V+ Jurkat cells were analyzed by flow
cytometry at 6, 12, 18, and 24 h p.i. Bars represent the standard error of two
independent experiments.
255J.-Y. Han et al. / Virology 359 (2007) 253–263Isolated CD4+ cells were infected with HSV-2 strain HG52 at an
MOI of 5 and analyzed for annexin V and PI binding at 24, 48,
and 72 h p.i. The percentage of annexin V+ cells (annexin
V+PI− and annexin V+PI+) was 32% in HSV-infected CD4+cells compared with 28% in mock-infected cells at 24 h p.i (Fig.
2A). At 48 h, 49% of HSV-infected CD4+ cells were annexin
V+ compared to 32% in mock-infected cells, while 52% of
HSV-infected cells and 40% of mock-infected cells were
annexin V+ at 72 h. The majority of the annexin V+ population
in mock-infected cells was also PI+, and the percentage of
annexin V+PI+ cells increased in both the mock and HSV-2-
infected cells over the time, likely reflecting the spontaneous
death that occurs with primary CD4+ cells in culture. This
background cell death may explain the lack of statistical
differences between mock- and HSV-infected cells when
comparing the percentages of annexin V+ cells. In contrast,
marked increases in the percentages of early apoptotic cells
(annexin V+PI−) were observed in HSV-infected cells compared
to mock-infected cells at all time points (Fig. 2B). Thus, the
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majority of increase in the percentage of annexin V+ cells in
HSV-infected cells compared to mock-infected cells.
To verify our findings, we analyzed mock- and HSV-infected
CD4+ cells for the presence of activated caspase-3. Cells were
labeled with antibody against activated caspase-3 and analyzed
by flow cytometry at 24, 48, and 72 h p.i. Similar to the results
using annexin V, a slight increase in cells with activated
caspase-3 was observed at 24 h p.i. for HSV-infected cells
compared to mock-infected cells, with larger increases detected
at 48 and 72 h p.i. (Fig. 2C).
Primary isolates of HSV-1 and HSV-2 induce apoptosis in
Jurkat cells
Primary clinical isolates of HSV-1 and HSV-2 were
evaluated for their apoptotic activity in infected Jurkat cells to
rule out the possibility that adaptation to laboratory growth was
responsible for the apoptotic activity. Jurkat cells were infected
with HSV at an MOI of 5 with clinical isolates of HSV-1 and
HSV-2 obtained from the University of Washington diagnostic
virology laboratory. Laboratory strains HSV-1 F and HSV-2
HG52 were utilized as controls. At 24 h p.i., all clinical isolates
of HSV showed induction of apoptosis at comparable levels to
laboratory strains, as measured by annexin V binding (Fig. 3).
Jurkat cells exposed to HSV-infected fibroblasts undergo
apoptosis
In vivo, T cells are most likely to encounter HSV via infected
keratinocytes (Posavad et al., 1998). A previous report from this
laboratory suggested that increased apoptosis was not present in
CTL within the first 5 h following an exposure to HSV-infected
fibroblasts despite demonstrated inhibition of cytolytic activity
and TCR signaling block (Sloan et al., 2003). Given our
findings in HSV-infected Jurkat cells, we addressed whether
Jurkat cells that are exposed to HSV-infected fibroblastsFig. 3. Induction of apoptosis after infection by laboratory or clinical isolates of
HSV. Annexin V binding was analyzed by flow cytometry in Jurkat cells that
were mock infected or infected with HSV for 24 h. Shown are mock cells and
cells infected with HSV-1 laboratory strain F, clinical isolates of HSV-1, HSV-2
laboratory strain HG52, and clinical isolates of HSV-2. Bars represent the
standard error of 3 independent experiments.undergo apoptosis at time points later than the first 5 h. Since
we previously demonstrated that acyclovir, a viral DNA
synthesis inhibitor, had no effect on HSV-mediated inhibition
of CTL cytolytic activity (Sloan et al., 2003), we conducted the
entire study in the presence of acyclovir to minimize infection
of Jurkat cells by replication competent virus.
The series of experiments was conducted in the same time
frame as our previous experimental model (Sloan et al., 2003).
Human primary fibroblasts were either mock-infected or
infected with HSV-2 HG52 for 6 h. Jurkat cells were exposed
to the fibroblasts for 4 h. Jurkat cells were then harvested and
analyzed for apoptosis at 0, 6, 12, and 24 h post exposure. We
observed a minimal difference in the percentage of apoptosis in
Jurkat cells exposed to HSV-infected fibroblasts at 0 h (i.e., after
4-h incubation with infected fibroblasts) by annexin V and PI
staining as compared with the control cells (Fig. 4A). A higher
percentage of annexin V+ cells was clearly appreciated at 6 h for
Jurkat cells exposed to HSV-infected fibroblasts, and we
observed a gradual increase in the percentage of apoptotic
cells over time to a maximum of 70% at 24 h (Fig. 4A).
Consistent with our finding in CTL (Sloan et al., 2003), a
minimal difference in the percentage of cells with activated
caspase-3 was noted at 0 h (Fig. 4B). Similar to the annexin V
and PI staining, a higher percentage of cells with activated
caspase-3 was noted at 6 h in the cells exposed to HSV-infected
fibroblasts, and caspase-3 activation increased over 24 h
(Fig. 4B).
To confirm the activity of caspase-3, we investigated the
cleavage of the DNA repair enzyme poly(ADP-ribose) poly-
merase (PARP) from a 115-kDa form to an 85-kDa fragment.
As shown in Fig. 4C, PARP is mostly expressed as a single 115-
kDa polypeptide in Jurkat cells exposed to mock-infected
fibroblasts. Some amount of baseline cleavage products could
be appreciated in Jurkat cells exposed to mock-infected
fibroblasts, consistent with a baseline apoptosis seen with
annexin V and activated caspase-3 staining. In Jurkat cells
exposed to HSV-infected fibroblasts, cleavage of PARP is
demonstrated by appearance of the 85-kDa fragment starting at
6 h post harvest with corresponding decreases in the 115-kDa
fragment. The processing of this protein was incomplete at all
examined time points, and full-length protein was still detected
at 24 h.
Inhibition of TCR signaling in Jurkat cells following
exposure to HSV-infected fibroblasts as previously described
in our model (Sloan et al., 2006) was confirmed by measuring
the percentage of cells with calcium mobilization above
baseline following stimulation of TCR with anti-CD3 mono-
clonal antibody (OKT-3). A 70% decrease in a percentage of
cells able to flux calcium was observed following TCR trigger
in HSV-exposed Jurkat cells at 0 h (Fig. 4D), and the inhibition
remained unchanged at 0, 6, 12, and 24 h (data not shown).
CD4+ cells isolated from human PBMC undergo apoptosis
following exposure to HSV-infected fibroblasts
To corroborate our findings with Jurkat cells, human CD4+
cells from PBMC were exposed to HSV-infected fibroblasts at
Fig. 5. Induction of apoptosis in CD4+ cells exposed to mock- or HSV-infected
fibroblasts. CD4+ cells were exposed to mock or HSV-2-infected fibroblasts.
CD4+ cells were then collected and analyzed for apoptosis by annexin Vand PI
staining at 0 h and 24 h post exposure. Percentages of annexin V+PI− (early
apoptotic) cells are shown for a representative flow cytometry analysis (out of 3
independent experiments).
Fig. 4. Jurkat cells exposed to HSV-2-infected fibroblasts undergo apoptosis and
show inhibition of TCR signaling. Percentages of Jurkat cells that are annexin
V+ (A) and activated caspase-3 positive (B) by flow cytometry at 0, 6, 12, and
24 h post exposure to mock- or HSV-2-infected fibroblasts. Bars represent
standard error of 3–6 independent experiments. (C) Full-length PARP (115 kDa)
and PARP cleavage products (85 kDa) in Jurkat cells exposed to mock and HSV-
2-infected fibroblasts at 0, 6, 12, and 24 h post exposure. (D) Calcium
mobilization following TCR stimulation of Jurkat cells exposed to mock- or
HSV-2-infected fibroblasts at 0 h post exposure. Calcium mobilization was
measured by 400-nm to 510-nm fluorescence emission ratio by flow cytometry.
Numbers in the upper right quadrant of each plot indicate the percentage of
Jurkat cells able to flux calcium as defined by greater than 95 percentile of
unstimulated baseline prior to addition of OKT-3 (vertical arrows). One
representative experiment out of 3 independent experiments is shown.
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PI binding at 24 h post harvest. 33% of CD4+ cells were annexin
V+PI− at 24 h following exposure to HSV-infected fibroblasts
as compared to 4% of cells exposed to mock-infected fibroblasts
(Fig. 5). Background necrosis and/or apoptosis in CD4+ cells
exposed to mock-infected fibroblasts were markedly lower
compared to when CD4+ cells were mock infected in theabsence of fibroblasts (Fig. 2A), allowing a clearer demonstra-
tion of the difference between the mock-exposed and HSV-
exposed cells in this set of experiments.
Inhibition of TCR signaling is observed in both apoptotic and
non-apoptotic HSV-2-infected Jurkat cells
To delineate the relationship between induction of apoptosis
and TCR signaling block, we evaluated the inhibition of TCR
signaling in apoptotic and non-apoptotic Jurkat cells following
HSV-2 infection. Jurkat cells were infected with HSV-2 HG52
for 6 h prior to analysis. Cells were simultaneously stained with
indo-1 and annexin V to evaluate calcium mobilization in
apoptotic and non-apoptotic populations by flow cytometry.
The apoptotic and non-apoptotic populations were separated by
forward scatter and annexin V staining. Both apoptotic and non-
apoptotic cells demonstrated inhibition of TCR signaling as
measured by decreases in the percentage of cells mobilizing
calcium following OKT-3 stimulation (Fig. 6).
Inhibition of apoptosis in Jurkat cells exposed to
HSV-2-infected fibroblasts has no effect on TCR
signaling block
To delineate further the interaction, if any, between induction
of apoptosis and inhibition of TCR signaling, we evaluated the
effect of a pan-caspase inhibitor, z-VAD-fmk, on Jurkat cells
exposed to HSV-infected fibroblasts. In this series of experi-
ments, Jurkat cells were incubated in medium containing 50 μM
z-VAD-fmk or DMSO solvent control for 30 min before
exposure to HSV-2-infected fibroblasts, throughout exposure,
Fig. 7. z-VAD-fmk inhibits apoptosis without affecting inhibition of TCR
signaling. (A) Percentages of annexin V+ Jurkat cells with standard error bars of
3 independent experiments as measured by flow cytometry. The percentage of
annexin V+ cells decreases following exposure to HSV-2-infected fibroblasts in
presence of 50 μM z-VAD-fmk compared to solvent control with DMSO. Bars
represent the standard error of 3 independent experiments. (B) Inhibition of TCR
signaling, as measured by decrease in the percentage of cells mobilizing calcium
following TCR stimulation, does not change in the presence of z-VAD-fmk.
Bars represent the standard error of 3 independent experiments. (C) Jurkat cells
exposed to mock-infected fibroblasts demonstrated phosphorylation of ERK1/2
following TCR stimulation. Inhibition of phosphorylation in Jurkat cells
exposed to HSV-2-infected cells was maintained in the presence of 20 μM or
50 μM z-VAD-fmk.
Fig. 6. Inhibition of TCR signaling pathway in apoptotic and non-apoptotic
populations in HSV-2-infected Jurkat cells. Jurkat cells were infected with HSV-
2 HG52 for 6 h prior to analysis. Cells were stained simultaneously with indo-1
and annexin V for detection of calcium flux in apoptotic and non-apoptotic
populations. (A) Annexin V stain shows both apoptotic and non-apoptotic cells
at 6 h p.i. (B) Apoptotic and non-apoptotic populations were gated individually
and assessed for the ability to mobilize calcium by flow cytometric analysis. (C)
Both populations demonstrate inhibition of TCR signaling pathway as shown by
the small percentages of cells (upper right quadrants) able to mobilize calcium
following OKT-3 stimulations (vertical arrows).
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exposure and analyzed for apoptosis and calcium mobilization
following TCR stimulation with OKT-3. Apoptosis in these
cells was inhibited with z-VAD-fmk as measured by annexin V
and PI staining at 24 h (Fig. 7A). However, z-VAD-fmk had no
discernible effect on the TCR signaling block, which occurred
to a similar degree in Jurkat cells with or without the caspase
inhibitor (Fig. 7B).
To verify this finding, we also investigated phosphorylation
status of extracellular signal-regulated protein kinases (ERK)
after stimulation with OKT-3 in these cells. ERK is one of the
intermediary molecules that become tyrosine phosphorylated
following activation of TCR signaling cascade. We previously
demonstrated that phosphorylation of ERK following OKT-3
stimulation is inhibited in T lymphocytes exposed to HSV-
infected fibroblasts (Sloan et al., 2006). As shown in Fig. 7C,
phosphorylation of ERK is inhibited in Jurkat cells exposed to
HSV-infected fibroblasts despite the presence of z-VAD-fmk.
Ramos cells exposed to HSV-2-infected fibroblasts undergo
apoptosis without inhibition of BCR signaling
We explored whether our findings in T cells were more
broadly applicable to all lymphocytes by investigating if
apoptosis was present in B cells exposed to HSV-infected
fibroblasts. The Epstein-Barr virus-negative human B cell
lymphoma line Ramos was used in these experiments. By
annexin Vand PI staining, we observed an increased percentageof apoptotic cells at 24 h and 48 h in Ramos cells exposed to
HSV-2-infected fibroblasts as compared to those cells exposed
to mock-infected fibroblasts (Fig. 8A).
Previous studies have shown that stimulation of B cell
antigen receptor (BCR) leads to apoptosis in Ramos cells with a
peak at 48 h (An et al., 2003; Mackus et al., 2002). In agreement
with these studies, BCR stimulation of Ramos cells exposed to
mock-infected fibroblasts, using anti-human IgM antibody,
resulted in apoptosis (data not shown). Similar results were seen
with activated caspase-3 staining (data not shown). However,
BCR stimulation of Ramos cells exposed to HSV-infected
fibroblasts did not increase apoptosis beyond that of Ramos
cells exposed to HSV-infected fibroblasts without BCR
stimulation, suggesting that these pro-apoptotic stimuli are not
additive (data not shown).
Previous studies from this and other laboratories have shown
that inhibition of cytotoxic activity occurs in natural killer cells,
lymphokine-activated killer cells, and CTL after exposure to
HSV-infected fibroblasts (Confer et al., 1990; Posavad et al.,
1993; Posavad and Rosenthal, 1992; Sloan et al., 2003; York
Fig. 8. Ramos cells undergo apoptosis without inhibition of BCR signaling
pathway following exposure to HSV-2-infected fibroblasts. Ramos cells were
exposed to mock or HSV-2-infected fibroblasts as described for Jurkat cells. (A)
Percentages of annexin V+ cells by flow cytometry analysis in Ramos cells
exposed to mock or HSV-2-infected fibroblasts at 24 h and 48 h post exposure
with standard error bars of 3 independent experiments. (B) Calcium
mobilization following BCR stimulation of Ramos cells exposed to mock- or
HSV-2-infected fibroblasts. Numbers in the upper right quadrant of each plot
indicate the percentages of Ramos cells that were able to flux calcium. The
percentages were determined by counting cells above the 95 percentile of
unstimulated baseline prior to the addition of anti-human IgM antibody (vertical
arrows). One representative experiment out of 7 independent experiments is
shown. (C) Left panel: phosphorylation of ERK after TCR stimulation in Jurkat
cells exposed to HSV-2-infected fibroblasts (solid line) compared to Jurkat cells
exposed to mock-infected fibroblasts (dashed line). Jurkat cells without TCR
stimulation (filled) are shown as control. Right panel: phosphorylation of ERK
with BCR stimulation of Ramos cells following exposure to HSV-2-infected
fibroblasts (solid line) compared to Ramos cells exposed to mock-infected
fibroblasts (dashed line). Unstimulated Ramos cells (filled) are shown as
control.
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the inhibition of the TCR signaling pathway in T lymphocytes
exposed to HSV-infected fibroblasts (Sloan et al., 2003, 2006).
If a BCR signaling block were present in Ramos cells exposed
to HSV-infected fibroblasts, such a block might explain why
BCR stimulation did not result in increased apoptosis. There-
fore, we assessed BCR signaling in Ramos cells following
exposure to HSV-infected fibroblasts.
Two arms of BCR signaling cascade were examined:
calcium mobilization and ERK phosphorylation. Ramos cells
were exposed to mock-infected or HSV-infected fibroblasts.Calcium mobilization was determined following stimulation
with anti-human IgM antibody. Ramos cells exposed to HSV-
infected fibroblasts demonstrated virtually no change in calcium
mobilization compared to control cells exposed to mock-
infected fibroblasts (Fig. 8B). In contrast, similar experiments in
Jurkat cells showed up to a 70% decrease in number of cells
able to mobilize calcium following TCR stimulation with OKT-
3 (Fig. 4D). Similarly, phosphorylation of ERK was not
inhibited in Ramos cells following exposure to HSV-2-infected
fibroblasts (Fig. 8C). Thus, although exposure to HSV-infected
fibroblasts resulted in apoptosis of Ramos cells, inhibition of
BCR signaling did not occur.
Discussion
In the present study, we showed that HSV infection results in
apoptosis of Jurkat cells and CD4+ cells isolated from human
PBMC. Exposure to HSV-infected fibroblasts resulted in
apoptosis of Jurkat cells, CD4+ cells, and Ramos cells. In
addition, we observed that clinical strains of HSV-1 and HSV-2
induced apoptosis in infected Jurkat cells at comparable levels
to the laboratory strains. The findings of our current study
suggest that an intriguing aspect of HSV modulation of host
immune response is through induction of apoptosis in key
immune effector cells. Given that most HSV-infected epithelial
cells do not show classic signs of apoptosis because certain viral
proteins act to inhibit the cell death process (Aubert and Blaho,
2001; Aubert and Jerome, 2003; Goodkin et al., 2004), the fact
that HSV induces apoptosis in lymphocytes has implications for
pathogenesis in vivo. Prevention of apoptosis in infected
keratinocytes and simultaneous induction of apoptosis in local
immune cells may tip the balance in favor of the virus, allowing
its survival and propagation. Thus, the ability of HSV to kill T
cells that are recruited to the site of reactivated lesions in vivo
could play a part in maintaining the viability of these lesions and
lengthening the time of viral shedding.
The precise mechanism(s) by which HSV induces apoptosis
in exposed lymphocytes is not clear. Given that HSV-infected
lymphocytes become apoptotic, we favor the idea that viral
element(s) are responsible for induction of apoptosis. Thus, T
cells that are exposed to infected fibroblasts may be induced to
die by viral element(s) that are transferred during cell to cell
contact. However, it is possible that lymphocytes could also be
induced to die by exposure to cellular products from HSV-
infected fibroblasts.
Previous studies indicated that apoptosis is initially induced
following HSV infection of epithelial cells such as HEp-2 and is
subsequently aborted by anti-apoptotic proteins (Aubert and
Blaho, 2001; Aubert and Jerome, 2003; Goodkin et al., 2004).
A previous report from our laboratory that suggested that at
early time points after infection, clinical HSV strains protected
Jurkat cells from apoptosis induced by anti-Fas antibody or UV
radiation (Jerome et al., 2001b). However, in our current study
we observed that clinical strains of HSV-1 and HSV-2 also
induced apoptosis. Since the same HSV-1 clinical strains were
used in both studies, we believe that this finding suggests that
the HSVanti-apoptotic proteins are functional in T cells, but are
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of viral infection. It may also be possible that an additional
apoptosis triggering mechanism occurs in HSV-infected
immune cells that bypass the viral anti-apoptotic mechanisms.
Alternatively, certain viral pathways designed to inhibit
apoptosis in other cell types may be inactive in lymphocytes,
resulting in apoptosis.
Considering the mechanism of apoptosis induction by HSV
in lymphocytes, it is important to note the differences in the
extent and the temporal timing of apoptosis in different cell
types in our study. In particular, primary CD4+ cells isolated
from human PBMC showed smaller increases in the percen-
tages of apoptotic cells as compared to Jurkat and Ramos cells.
It is possible that these CD4+ cells are more resistant to
apoptotic stimulus than the transformed cell lines. However, the
percentage of apoptotic cells in Jurkat and CD4+ cells were
similar following an incubation with anti-Fas monoclonal
antibody in our hands (data not shown), suggesting equal
susceptibilities to stimulation of the Fas pathway in these two
cell types. An alternative explanation may be that certain
lineages of CD4+ cells may be innately resistant to infection by
HSV, and thus the pro-apoptotic viral element(s) may not be
present in these cells. We are currently undertaking studies to
decipher the precise mechanism of cell death in HSV-exposed T
cells.
Given our findings of apoptosis in Jurkat cells exposed to
HSV-2-infected fibroblasts, it was important to reexamine our
findings of TCR signal block in similarly exposed Jurkat cells.
CD95/Fas ligation, a common means of inducing apoptosis,
also leads to inhibition of TCR signaling, as measured by
calcium mobilization and ERK1/2 phosphorylation (Kovacs
et al., 1999; Kovacs and Tsokos, 1995; Lepple-Wienhues et al.,
1999; Yankee et al., 2001). However, CD95/Fas-mediated
inhibition of TCR signal transduction is thought to be secondary
to caspase-mediated cleavage of adaptor proteins (Yankee et al.,
2001). Jurkat cells exposed to HSV-2-infected fibroblasts
demonstrated inhibition of TCR signal transduction despite
the presence of pan-caspase inhibitor, z-VAD-fmk, suggesting
that inhibition is not mediated by caspases. Because the
inhibition of apoptosis with z-VAD-fmk was not complete in
Jurkat cells, we cannot completely rule out the possibility that
small amounts of activated caspases could lead to inhibition of
TCR signal transduction. In addition, earlier events in the
apoptotic pathway may not be affected by z-VAD-fmk, and
these events could mediate the inhibition of TCR signal
transduction. However, TCR signal block in HSV-exposed
Jurkat cells could be demonstrated before the cells showed signs
of apoptosis, suggesting a temporal dissociation between the
two outcomes. Thus, it seems likely that while caspase
activation may contribute to the overall dysfunction of T cells,
an additional mechanism leading to inhibition of the TCR signal
must exist that is independent of caspase activation and
subsequent apoptosis.
In conclusion, our results demonstrate that HSV induces
apoptosis in both immortalized and primary lymphocytes.
Apoptosis occurs in both infected T cells and T cells that are
exposed to HSV-infected fibroblasts. Apoptosis is also observedin B cells that are exposed to HSV-infected fibroblasts, but BCR
signaling is unaffected. Our findings suggest that the induction
of apoptosis and the inhibition of TCR signal in T cells exposed
to HSV-infected fibroblasts are mediated by independent
mechanisms. A more complete understanding of these immune
modulatory mechanisms may lead to better management of
HSV infections.
Material and methods
Cells and viruses
Vero (African green monkey kidney epithelial cells), Jurkat
(clone E6-1 human acute T cell leukemia), and Ramos (human
Burkitt lymphoma) cell lines were obtained from the American
Type Culture Collection (Manassas, VA). Human primary
fibroblasts were obtained from foreskin samples. Vero cells and
fibroblasts were maintained in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS). Jurkat and Ramos cells were maintained in RPMI 1640
supplemented with 10% FBS.
To isolate human CD4+ cells, human blood donor white
blood cell reduction filters (Pall Corporation, East Hills, NY)
were obtained from Puget Sound Blood Center (Seattle, WA).
Cells were extracted by alternating back flushes with phos-
phate-buffered saline (PBS) and 1 mM EDTA in PBS. PBMC
were isolated over Ficoll-Hypaque (Fred Hutchinson Cancer
Research Center, Seattle, WA). Isolated PBMC were stimulated
with 5 μg/ml phytohemagglutinin in RPMI-1640 with 10% FBS
for 48 h and then maintained with IL-2 in RPMI-1640 with 10%
FBS. CD4+ cells were positively selected to >95% purity using
MACS CD4 microbeads (Miltenyi Biotec Inc., Auburn, CA)
immediately prior to experiments.
HSV-1 strain F and HSV-2 strain HG52 were grown in Vero
cells. Clinical isolates of HSV-1 and HSV-2 were obtained from
the University of Washington diagnostic virology laboratory
(Seattle, WA) and passaged twice in Vero cells to prepare viral
stocks. Titers of viruses were determined in Vero cells.
Infection of T cells with HSV-1 and HSV-2
Jurkat cells were mock infected or infected with laboratory
or clinical isolates of HSV-1 and HSV-2 in RPMI-1640 with
10% FBS. CD4+ cells were infected with HSV-2 strain HG52 in
RPMI-1640 with 10% FBS and IL-2. For each infection, viral
inoculum corresponding to the MOI of 5 was added to the cells
at less than 5% of total volume, and remained present
throughout the incubation period. Infected cells were main-
tained in medium until collections at 6 h, 24 h, 48 h, and/or 72 h
for detection of apoptotic markers and analysis of TCR
function.
Exposure of lymphocytes to HSV-infected fibroblasts
For the exposure of Jurkat and Ramos cells to HSV-infected
fibroblasts, fibroblasts were grown to confluency in flat bottom
plates and then either mock infected or infected with HSV-2
261J.-Y. Han et al. / Virology 359 (2007) 253–263HG52 at an MOI of 10 in DMEM with 2% FBS and 100 μM
acyclovir (Sigma-Aldrich, St. Louis, MO). Fibroblasts were
rocked during the 2-h infection period. Fibroblasts were then
washed with PBS, and medium was changed to DMEM with
10% FBS and 100 μM acyclovir. After 6-h infection, fibroblasts
were washed with PBS, and lymphocytes were added at 2:1
ratio (lymphocytes to fibroblasts) in RPMI-1640 with 10% FBS
and 100 μM acyclovir. After 4-h incubation, lymphocytes were
harvested and maintained in fresh medium with 100 μM
acyclovir until each time point.
For the exposure of CD4+ cells to HSV-infected fibroblasts,
the experiments were conducted as above without acyclovir.
For experiments with the pan-caspase inhibitory peptide z-
VAD-fmk (Calbiochem, San Diego, CA), 20 or 50 μM of
inhibitor was added to Jurkat cells 30 min prior to exposure to
HSV-2-infected fibroblasts and was present at the same
concentration throughout the duration of the experiments.
Detection of apoptosis
Lymphocytes were collected at the stated times. Phosphati-
dylserine exposure on apoptotic cells was measured using
annexin V conjugated with FITC (Molecular Probes, Eugene,
OR) following the manufacturer's instructions. Loss of
membrane integrity was measured with PI (Molecular Probes).
The percentage of cells with activated caspase-3 was detected
using FITC- or phycoerythrin-conjugated, affinity purified
polyclonal rabbit anti-caspase-3 antibody (BD Biosciences,
San Jose, CA) following permeabilization of the cells as
previously described (Jerome et al., 2003). ≥10,000 events/
sample were acquired using a FACSCan or LSR1 flow
cytometer (BD Biosciences) and analyzed by FlowJo (Tree
Star, Ashland, OR) and Cell Quest (BD Biosciences) software.
To determine the cleavage of PARP, cells were lysed in lysis
buffer (20 mMTris–HCl, pH 7.4, 10 mMEDTA, 100 mMNaCl,
1% NP-40, 0.01% sodium azide, 5 mM sodium orthovanadate,
10 mM phenylmethylsulfonyl fluoride, 10 μg/ml L-1-chlor-3-
(4-tosylamido)-4-phenyl-2-butanone (TPCK), and 10 μg/ml L-
1-chlor-3-(4-tosylamido)-7-amino-2-heptanon-hydrochloride
(TLCK)). Nuclear and cellular debris were removed by
centrifugation. Lysates were diluted 3:1 in denaturing buffer
(10% SDS, 10% β-mercaptoethanol, 20% glycerol, 1%
bromophenol blue, and 120 mM Tris–HCl, pH 6.8) and boiled
for 5 min. Lysates from 5×105 cells/sample were resolved by 4–
12% SDS-PAGE and transferred onto a nitrocellulose mem-
brane. The membrane was blocked by incubating with 5% milk
in PBS with 0.05% Tween-20 and probed with anti-PARP
mouse monoclonal antibody (Zymed, South San Francisco, CA)
overnight at 4 °C. The secondary antibody used was goat anti-
mouse IgG conjugated to horseradish peroxidase (Cell Signal-
ing, Beverly, MA). The blot was visualized by chemilumines-
cence with SuperSignal West Pico kit (Pierce, Rockford, IL).
Detection of calcium mobilization
Jurkat and Ramos cells were exposed to mock or HSV-2
HG52 infected fibroblasts as described above. Lymphocyteswere then loaded with 2 μMof the Ca+ indicator dye indo-1 AM
(Molecular Probes) as previously described (Sloan et al., 2006).
Samples were analyzed on a LSR1 flow cytometer. After
obtaining a baseline, lymphocytes were stimulated for calcium
mobilization with either 2 μg/ml OKT-3 (OrthoMcNeil, Red-
wood City, CA) for Jurkat cells or 5 μg/ml goat anti-human IgM
(mu chain specific, Zymed) for Ramos cells. 400-nm to 510-nm
fluorescence emission ratio versus time was plotted in Cell
Quest software for analysis.
Detection of phosphorylated ERK1/2
Following exposure to mock or HSV-2 HG52 infected
fibroblasts, Jurkat or Ramos cells were stimulated for 10 min at
37 °C with 10 μg/ml OKT-3 or anti-human IgM antibody
respectively. Cells were then fixed, permeabilized, and stained
as previously described (Sloan et al., 2006). Cells were analyzed
on a FACScan flow cytometer and Cell Quest software.
Alternatively, cells were lysed following stimulation and
immunoblotting was carried out as described above for the
detection of PARP cleavage. Phosphorylated ERK1/2 was
detected using rabbit polyclonal antibody against phospho-ERK
(Thr202/Tyr204, Cell Signaling) and horseradish peroxidase
conjugated goat anti-rabbit antibody (Cell Signaling). Total
ERK1/2 protein was detected using rabbit polyclonal p44/42
MAP kinase antibody (Cell Signaling).
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